BR0013504A - Inibidores da integrina alfav beta3 - Google Patents

Inibidores da integrina alfav beta3

Info

Publication number
BR0013504A
BR0013504A BR0013504-6A BR0013504A BR0013504A BR 0013504 A BR0013504 A BR 0013504A BR 0013504 A BR0013504 A BR 0013504A BR 0013504 A BR0013504 A BR 0013504A
Authority
BR
Brazil
Prior art keywords
alfav
integrin inhibitors
beta3 integrin
inhibitors
integrin ligands
Prior art date
Application number
BR0013504-6A
Other languages
English (en)
Inventor
Alfred Jonczyk
Oliver Schadt
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0013504A publication Critical patent/BR0013504A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: "INIBIDORES DA INTEGRINA ALFA~ v~ BETA~ 3~". A invenção descreve novos compostos da fórmula I, biologicamente ativos como ligandos da integrina <224>~ v~<225>~ 3~ X-Y-Z-R^ 1^-CH~ 2~-R^ 2^ (R^ 4^) -CH~ 2~-CO-R~ 5~ I, em que X, Y, Z, R^ 1^, R^ 2^, R^ 4^ e R^ 5^ têm os significados indicados na reivindicação 1, e seus sais e solvatos fisiologicamente aceitáveis.
BR0013504-6A 1999-08-24 2000-08-04 Inibidores da integrina alfav beta3 BR0013504A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19939981A DE19939981A1 (de) 1999-08-24 1999-08-24 Neue Inhibitoren des Integrins alphavß3
PCT/EP2000/007591 WO2001014338A1 (de) 1999-08-24 2000-08-04 NEUE INHIBITOREN DES INTEGRINS αVβ¿3?

Publications (1)

Publication Number Publication Date
BR0013504A true BR0013504A (pt) 2002-05-07

Family

ID=7919343

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013504-6A BR0013504A (pt) 1999-08-24 2000-08-04 Inibidores da integrina alfav beta3

Country Status (17)

Country Link
EP (1) EP1206454A1 (pt)
JP (1) JP2003507458A (pt)
KR (1) KR20020016651A (pt)
CN (1) CN1370147A (pt)
AU (1) AU6570500A (pt)
BR (1) BR0013504A (pt)
CA (1) CA2382850A1 (pt)
CZ (1) CZ2002523A3 (pt)
DE (1) DE19939981A1 (pt)
HK (1) HK1049666A1 (pt)
HU (1) HUP0203697A3 (pt)
MX (1) MXPA02001861A (pt)
NO (1) NO20020886L (pt)
PL (1) PL352989A1 (pt)
SK (1) SK2282002A3 (pt)
WO (1) WO2001014338A1 (pt)
ZA (1) ZA200202287B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
ES2436170T3 (es) * 2003-12-03 2013-12-27 The Scripps Research Institute Anticuerpos y péptidos específicos de la integrina alfa II beta3
EP1802618A1 (en) * 2004-10-14 2007-07-04 Pharmacia Corporation Biphenyl integrin antagonists
HUE053620T2 (hu) * 2016-11-08 2021-07-28 Bristol Myers Squibb Co Pirrol amidok mint alfa-V integrin inhibitorok

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325264A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
AU717283B2 (en) * 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
CN1299282A (zh) * 1998-03-10 2001-06-13 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂

Also Published As

Publication number Publication date
AU6570500A (en) 2001-03-19
SK2282002A3 (en) 2002-06-04
KR20020016651A (ko) 2002-03-04
CA2382850A1 (en) 2001-03-01
WO2001014338A1 (de) 2001-03-01
CZ2002523A3 (cs) 2002-05-15
DE19939981A1 (de) 2001-03-01
NO20020886D0 (no) 2002-02-22
PL352989A1 (en) 2003-09-22
HUP0203697A3 (en) 2004-04-28
CN1370147A (zh) 2002-09-18
JP2003507458A (ja) 2003-02-25
NO20020886L (no) 2002-02-22
ZA200202287B (en) 2003-08-27
MXPA02001861A (es) 2004-09-06
EP1206454A1 (de) 2002-05-22
HK1049666A1 (zh) 2003-05-23
HUP0203697A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
BR0215042A (pt) fenil-naftalenos substituìdos como agentes estrogênicos
BR9913225A (pt) Novos agentes antibacterianos de isoxazolinona
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
ME00601B (me) Modified factor viii
BR9815518A (pt) Agentes antibacterianos de oxazolidinona tendo funcionalidade de tiocarbonila
EP1233013A4 (en) phenylalanine derivatives
BR9916678A (pt) Inibidores de trombina
FR2787313B1 (fr) Implant d&#39;osteosynthese
ATE234812T1 (de) Integrin antagonisten
BR9913705A (pt) Métodos de tratamento de mieloma múltiplo e reabsorção de tecido ósseo induzido por mieloma utilizando antagonistas de integrin
ATE337008T1 (de) Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen salzen
BR0010349C1 (pt) Derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores
FR2794019B1 (fr) Implant d&#39;osteosynthese
BR0013502A (pt) Inibidores da integrina alfav beta3
BR0013504A (pt) Inibidores da integrina alfav beta3
BR0012291A (pt) Fenoxifluorpirimidinas
BR0014311A (pt) Quinazolinonas
BR0317383A (pt) Metabólitos agonista de vasopressina biologicamente ativos
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
HRP20010764B1 (en) Prucalopride oral solution
DE60121048D1 (de) PYRAZINOi1&#39;2&#39;:1,6öPYRIDOi3,4-BöINDOLDERIVATE
BR0014294A (pt) Quinazolinonas
FR2718923B1 (fr) Composition désinfectante en solution aqueuse renfermant de l&#39;orthophtalaldéhyde.
DK1280784T3 (da) Biologisk aktive 4H-benzo[1,4]oxazin-3-oner
NO20032977L (no) Anvendelse av biologisk materiale inneholdende tredimensjonale oppsatsstrukturer av hyaluronsyrederivater for fremstilling av implantater i forbindelse med artroskopi.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007.